Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Nursing | Oncology | Orthopedics | Surgery | Journal

Back to Journal Articles

IVC Filters Confirmed Effective for Patients at Embolism Risk

Last Updated: June 21, 2012.

Inferior vena cava filters are safe for use in patients at higher risk for venous thromboembolic events while undergoing major spinal surgery, according to research published in the June issue of the Journal of Spinal Disorders & Techniques.

 

No complications related to filter use in case series of patients undergoing major spinal surgery

Share |

Comments: (0)

Tell-a-Friend

 

  Advertisement

THURSDAY, June 21 (HealthDay News) -- Inferior vena cava (IVC) filters are safe for use in patients at higher risk for venous thromboembolic events (VTEs) while undergoing major spinal surgery, according to research published in the June issue of the Journal of Spinal Disorders & Techniques.

Justin M. Dazley, M.D., from the Stony Brook University Hospital in New York City, and colleagues reviewed cases of patients undergoing major spinal surgery from 2006 to 2009 who had IVC filters placed for VTE prophylaxis. Patients with two or more VTE risk factors were included. Intercepted emboli were identified using cavograms obtained at the time of attempted filter retrieval.

The researchers found that, at attempted filter retrieval, about 17 percent of patients had entrapped thrombus present, and an additional 17 percent of filters changed position within the IVC and could not be retrieved. There were no complications related to IVC filter use. None of the patients experienced symptomatic pulmonary embolism. One patient developed a deep vein thrombus requiring pharmacologic intervention and one patient developed superficial phlebitis.

"These findings show that the decreased rate of pulmonary embolism observed in this and other series is likely because of the use of IVC filters, rather than sampling bias inherent when studying a relatively rare problem," the authors write.

One author disclosed financial ties to the medical device industry.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: AHA: Concentrates Promising for Reversal of Apixaban Next: Genetic Contribution Detected in Responses to Opioids

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

 
     

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2016
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.